Your browser is no longer supported. Please, upgrade your browser.
Sana Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own11.80% Shs Outstand119.13M Perf Week-15.49%
Market Cap3.12B Forward P/E- EPS next Y-1.85 Insider Trans0.00% Shs Float85.86M Perf Month-43.47%
Income-285.30M PEG- EPS next Q-0.39 Inst Own11.70% Short Float3.89% Perf Quarter-53.55%
Sales- P/S- EPS this Y-118.20% Inst Trans- Short Ratio6.06 Perf Half Y-
Book/sh7.40 P/B2.46 EPS next Y-1.60% ROA- Target Price- Perf Year-
Cash/sh5.59 P/C3.25 EPS next 5Y- ROE- 52W Range16.28 - 44.60 Perf YTD-48.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.26% Beta-
Dividend %- Quick Ratio27.50 Sales past 5Y- Gross Margin- 52W Low11.61% ATR1.95
Employees263 Current Ratio27.50 Sales Q/Q- Oper. Margin- RSI (14)31.44 Volatility11.50% 9.49%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.32 Prev Close16.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume550.55K Price18.17
Recom2.20 SMA20-23.12% SMA50-33.89% SMA200-38.89% Volume726,937 Change9.13%
Mar-01-21Initiated Morgan Stanley Overweight $40
Mar-01-21Initiated JP Morgan Neutral $35
Mar-01-21Initiated Goldman Neutral $40
Mar-01-21Initiated BofA Securities Buy $45
May-05-21 04:05PM  
May-04-21 04:05PM  
Apr-27-21 04:35PM  
Apr-09-21 09:00AM  
Mar-30-21 09:30AM  
Mar-24-21 04:10PM  
Mar-17-21 09:00AM  
Feb-08-21 05:24PM  
Feb-03-21 11:22PM  
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.